Report cover image

Blood Product Market

Publisher Evolve Business Intelligence
Published Apr 14, 2025
SKU # EVBI19932153

Description

The Blood Product Market is anticipated to reach USD 0.47 billion by 2033, growing from USD 0.33 billion in 2023 at a compound annual growth rate (CAGR) of 4.32% over the forecast period. Blood products are medical substances derived from human blood used for therapeutic purposes. These products encompass whole blood, blood components such as red blood cells, white blood cells, platelets, and plasma, as well as plasma-derived products like clotting factors and immunoglobulins. They play a critical role in treating various medical conditions including anemia, clotting disorders, and immune deficiencies, and are essential in surgical and trauma care. These products are meticulously collected, processed, and tested to ensure their safety and compatibility for transfusions and other medical applications.

The latest research report by Evolve Business Intelligence explores the various factors influencing the global market. It includes an analysis of the current market size, forecasts for key segments and regions, and the driving forces behind market growth. The report examines the potential impacts of key trends on business strategies and provides a SWOT analysis of critical sectors for each major competitor and customer group. This valuable data highlights the conglomerates likely to impact the industry, crucial for any company planning to invest strategically over the next five years. These insights complement our initial quantitative study, aiding in new investments and strategic planning to mitigate threats in existing sectors.

Segments covered

By Type (Coagulation Factor, Immune Globulin, Albumin)
By Application (Surgery, Therapy, Immunity)

Key players

GRIFOLS
RELIANCE LIFE SCIENCE
BHARAT SERUMS AND VACCINES
INTAS PHARMACEUTICALS
HEMARUS
TAKEDA PHARMACEUTICAL COMPANY
OCTAPHARMA
PLASMAGEN BIOSCIENCES
NEXUS LIFECARE
KEDRION
BPL (BIO PRODUCTS LABORATORY LTD.)
HUALAN BIOLOGICAL ENGINEERING INC
BAXTER
MITSUBISHI TANABE PHARMA
CSL
SHANGHAI RAAS

Table of Contents

Chapter 1. Executive Summary
Chapter 2. Scope Of The Study
2.1. Market Definition
2.2. Scope Of The Study
2.2.1. Objectives of Report
2.2.2. Limitations
2.3. Market Structure
Chapter 3. Evolve BI Methodology
Chapter 4. Market Insights and Trends
4.1. Supply/ Value Chain Analysis
4.1.1. Raw End Users Providers
4.1.2. Manufacturing Process
4.1.3. Distributors/Retailers
4.1.4. End-Use Industry
4.2. Porter’s Five Forces Analysis
4.2.1. Threat Of New Entrants
4.2.2. Bargaining Power Of Buyers
4.2.3. Bargaining Power Of Suppliers
4.2.4. Threat Of Substitutes
4.2.5. Industry Rivalry
4.3. Impact Of COVID-19 on the Blood Product Market
4.3.1. Impact on Market Size
4.3.2. End-Use Industry Trend, Preferences, and Budget Impact
4.3.3. Regulatory Framework/Government Policies
4.3.4. Key Players' Strategy to Tackle Negative Impact
4.3.5. Opportunity Window
4.4. Technology Overview
12.28. Macro factor
4.6. Micro Factor
4.7. Demand Supply Gap Analysis of the Blood Product Market
4.8. Import Analysis of the Blood Product Market
4.9. Export Analysis of the Blood Product Market
Chapter 5. Market Dynamics
5.1. Introduction
5.2. DROC Analysis
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Opportunities
5.2.4. Challenges
5.3. Patent Analysis
5.4. Industry Roadmap
5.5. Parent/Peer Market Analysis
Chapter 6. India Blood Product Market, By Type
6.1. Introduction
6.2. Coagulation Factor
6.3. Immune Globulin
6.4. Albumin
Chapter 7. India Blood Product Market, By Application
7.1. Introduction
7.2. Surgery
7.3. Therapy
7.4. Immunity
Chapter 8. Company Landscape
8.1. Introduction
8.2. Vendor Share Analysis
8.3. Key Development Analysis
8.4. Competitor Dashboard
Chapter 9. Company Profiles
9.1. GRIFOLS
9.1.1. Business Overview
9.1.2. Government & Defense Analysis
9.1.2.1. Government & Defense – Existing/Funding
9.1.3. Product Portfolio
9.1.4. Recent Development and Strategies Adopted
9.1.5. SWOT Analysis
9.2. RELIANCE LIFE SCIENCE
9.2.1. Business Overview
9.2.2. Government & Defense Analysis
9.2.2.1. Government & Defense – Existing/Funding
9.2.3. Product Portfolio
9.2.4. Recent Development and Strategies Adopted
9.2.5. SWOT Analysis
9.3. BHARAT SERUMS AND VACCINES
9.3.1. Business Overview
9.3.2. Government & Defense Analysis
9.3.2.1. Government & Defense – Existing/Funding
9.3.3. Product Portfolio
9.3.4. Recent Development and Strategies Adopted
9.3.5. SWOT Analysis
9.4. INTAS PHARMACEUTICALS
9.4.1. Business Overview
9.4.2. Government & Defense Analysis
9.4.2.1. Government & Defense – Existing/Funding
9.4.3. Product Portfolio
9.4.4. Recent Development and Strategies Adopted
9.12.28. SWOT Analysis
9.5. HEMARUS
9.5.1. Business Overview
9.5.2. Government & Defense Analysis
9.5.2.1. Government & Defense – Existing/Funding
9.5.3. Product Portfolio
9.5.4. Recent Development and Strategies Adopted
9.5.5. SWOT Analysis
9.6. TAKEDA PHARMACEUTICAL COMPANY
9.6.1. Business Overview
9.6.2. Government & Defense Analysis
9.6.2.1. Government & Defense – Existing/Funding
9.6.3. Product Portfolio
9.6.4. Recent Development and Strategies Adopted
9.6.5. SWOT Analysis
9.7. OCTAPHARMA
9.7.1. Business Overview
9.7.2. Government & Defense Analysis
9.7.2.1. Government & Defense – Existing/Funding
9.7.3. Product Portfolio
9.7.4. Recent Development and Strategies Adopted
9.7.5. SWOT Analysis
9.8 PLASMAGEN BIOSCIENCES
9.8.1. Business Overview
9.8.2. Government & Defense Analysis
9.8.2.1. Government & Defense – Existing/Funding
9.8.3. Product Portfolio
9.8.4. Recent Development and Strategies Adopted
9.8.5. SWOT Analysis
9.9 NEXUS LIFECARE
9.9.1. Business Overview
9.9.2. Government & Defense Analysis
9.9.2.1. Government & Defense – Existing/Funding
9.9.3. Product Portfolio
9.9.4. Recent Development and Strategies Adopted
9.9.5. SWOT Analysis
9.10. KEDRION
9.10.1. Business Overview
9.10.2. Government & Defense Analysis
9.10.2.1. Government & Defense – Existing/Funding
9.10.3. Product Portfolio
9.10.4. Recent Development and Strategies Adopted
9.10.5. SWOT Analysis

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us